文献速递胸部肿瘤消化系统肿瘤骨软组织肉瘤与黑色素瘤

接受KRASG12C抑制剂治疗的患者临床获得性耐药变异的基因组图谱

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.
PubMed 文献 · Ann Oncol · 2025-02-04

该研究分析了两个美国癌症中心及六项已发表研究中143例接受KRASG12C抑制剂治疗患者的进展后cfDNA测序数据,并结合工程化细胞模型验证候选耐药驱动因素。结果显示46%的患者出现获得性RAS/MAPK变异,结直肠癌中比例显著高于非小细胞肺癌(69% vs 26%,P<0.001)。临床前数据提示新型(K)RAS抑制剂可能克服许多此类耐药变异。

要点

  • 143例接受KRASG12C抑制剂治疗患者中,46%出现获得性RAS/MAPK变异。
  • 结直肠癌获得性RAS/MAPK变异比例显著高于非小细胞肺癌(69% vs 26%,P<0.001)。
  • 临床前数据显示新型(K)RAS抑制剂可能克服许多获得性耐药变异。

核心结论

  • 获得性RAS/MAPK变异是KRASG12C抑制剂耐药的复发性驱动因素,在结直肠癌中检出率高于非小细胞肺癌。
  • 临床前数据提示新型(K)RAS抑制剂可能克服许多此类获得性耐药变异。

研究设计与样本

  • 评估两个美国癌症中心接受KRASG12C抑制剂治疗患者进展后cfDNA样本的基因组测序数据,并结合六项已发表研究的数据。
  • 共分析143例患者,其中非小细胞肺癌68例、结直肠癌58例;109例接受单药KRASG12C抑制剂治疗,30例联合抗EGFR抗体治疗。
  • 采用工程化细胞模型的细胞活力实验对候选耐药驱动因素进行功能验证,并评估新型KRAS抑制剂。

主要发现

  • 46%的患者(n=66)出现RAS/MAPK变异,39%(n=56)出现一个或多个新的KRAS变异,23%(n=33)出现多个并发变异。
  • 获得性变异图谱包括KRAS激活突变(25%)、KRAS扩增(22%)、RAF/MAPK突变/融合(21%)、KRAS switch-II口袋突变(14%)和NRAS/HRAS突变(8%)。
  • 结直肠癌中一个或多个获得性RAS/MAPK变异的患者比例显著高于非小细胞肺癌(69% vs 26%,P<0.001)。
  • 功能研究证实大多数变异为耐药驱动因素。
  • Sotorasib、adagrasib和divarasib对KRAS switch-II口袋突变表现出不同活性,但均对RAS(ON) G12C选择性三复合体抑制剂RM-018有响应;KRAS选择性抑制剂Pan KRAS-IN-1有效靶向KRAS激活突变,RAS(ON)多选择性三复合体抑制剂RMC-7797对所有RAS变异均表现出高效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutant-selective inhibitors of KRASG12C (KRASG12Ci) have demonstrated efficacy in KRASG12C cancers. However, resistance invariably develops, resulting in short-lived responses. We aimed to define the genomic landscape of acquired resistance to KRASG12Ci and to elucidate whether novel classes of KRAS inhibitors can overcome these resistance mechanisms. METHODS: To assess clinical frequencies of acquired resistance alterations, we evaluated genomic sequencing data from postprogression cell-free DNA samples in patients treated with KRASG12Ci at two United States cancer centers, alongside data from six previously published studies. Cell viability assays using engineered cell models were employed to functionally validate candidate resistance drivers and to evaluate novel classes of KRAS inhibitors. RESULTS: A total of 143 patients were analyzed. Most patients had non-small-cell lung cancer (NSCLC, n = 68) or colorectal cancer (CRC, n = 58) and were treated with single-agent KRASG12Ci (n = 109) or combined with anti-EGFR antibodies (n = 30). RAS/MAPK alterations emerged in 46% of patients (n = 66), with 39% developing one or more new KRAS alterations (n = 56) and 23% (n = 33) showing multiple concurrent alterations. The genomic landscape of acquired alterations included KRAS-activating mutations (25% of patients), KRAS amplifications (22%), RAF/MAPK mutations/fusions (21%), KRAS switch-II pocket mutations (14%), and NRAS/HRAS mutations (8%). Notably, the proportion of patients with one or more acquired RAS/MAPK alteration was significantly higher in CRC compared with NSCLC (69% versus 26%, P < 0.001). Functional studies confirmed most alterations as resistance drivers. Sotorasib, adagrasib, and divarasib demonstrated distinct activity against KRAS switch-II pocket mutations, yet all were responsive to the RAS(ON) G12C-selective tri-complex inhibitor RM-018. The KRAS-selective inhibitor Pan KRAS-IN-1 effectively targeted KRAS-activating mutations, and the RAS(ON) multiselective tri-complex inhibitor RMC-7797 demonstrated high potency across all RAS alterations. CONCLUSIONS: Acquired RAS/MAPK alterations are recurrent drivers of resistance to KRASG12Ci detected in CRC and, less frequently, in NSCLC. Preclinical data suggest that novel (K)RAS inhibitors may overcome many of these resistance alterations.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Riedl JM, Fece de la Cruz F, Lin JJ, et al. Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors. Ann Oncol. 2025. PMID: 39914665. doi:10.1016/j.annonc.2025.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。